Metabolic models
In vitro and animal metabolic disease research contexts.
Tirzepatide — A Dual GIP / GLP-1 Receptor Agonist
A scientific overview for preclinical research, with references to peer-reviewed literature.
Mechanism Overview
Tirzepatide is a 39-amino-acid peptide with a C20 fatty di-acid moiety. It activates both the GIP and GLP-1 receptors, engaging dual incretin pathways studied in metabolic disease models.
- Dual incretin receptor activation (GIP + GLP-1)
- Published half-life ≈ 5 days
- References: SURPASS / SURMOUNT trial literature (DOI-linked)
Research Applications
Receptor signaling
Comparative pharmacology versus semaglutide and other incretins.
Formulation
Stability, reconstitution and delivery studies.
References / DOIs
- Dual receptor agonist design — Nature / NEJM SURMOUNT series (peer-reviewed).
- Comparative pharmacology — published receptor-binding assays.
Request a sample for your study
Reach us on WhatsApp with your institution and intended use.
Chat on WhatsApp